6-cyclohexyl-5-(furan-2-yl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylic acid | 632365-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并嘧啶类
• 英文名称: 6-cyclohexyl-5-(furan-2-yl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylic acid
• CAS: 632365-25-4
• 化学式: C₁₇H₁₇N₃O₄
• 分子量: 327.34
• InChiKey: AVPVNQILTWINLA-UHFFFAOYSA-N

物化性质

• 沸点：
  565.7±60.0 °C(Predicted)
• 密度：
  1.55±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.03
• 重原子数：
  24.0
• 可旋转键数：
  3.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  100.6
• 氢给体数：
  2.0
• 氢受体数：
  5.0

反应信息

• 作为反应物：
  描述：

  6-cyclohexyl-5-(furan-2-yl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylic acid 、 L-酪氨酸 在 N,N-二异丙基乙胺 、 Methanaminium,N-[(dimethylamino)(3H-1,2,3-triazolo[4,5-b]pyridin-3-yloxy)methylene]-N-methyl-, hexafluorophosphate(1-) 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 2.0h， 以90%的产率得到
  参考文献：
  名称：

  Discovery of 4H-pyrazolo[1,5-a]pyrimidin-7-ones as potent inhibitors of hepatitis C virus polymerase

  摘要：

  A series of 4H-pyrazolo[1,5-a]pyrimidin-7-one derivatives was synthesized and evaluated for inhibitory activity against HCV NS5B RNA-dependent RNA polymerase. A number of these compounds exhibited potent activity in enzymatic assay. The synthesis and structure-activity relationship are also described. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.124
• 作为产物：
  描述：

  在 lithium hydroxide 作用下， 以 四氢呋喃 为溶剂， 反应 14.0h， 以95%的产率得到6-cyclohexyl-5-(furan-2-yl)-7-oxo-4,7-dihydropyrazolo[1,5-a]pyrimidine-2-carboxylic acid
  参考文献：
  名称：

  Discovery of 4H-pyrazolo[1,5-a]pyrimidin-7-ones as potent inhibitors of hepatitis C virus polymerase

  摘要：

  A series of 4H-pyrazolo[1,5-a]pyrimidin-7-one derivatives was synthesized and evaluated for inhibitory activity against HCV NS5B RNA-dependent RNA polymerase. A number of these compounds exhibited potent activity in enzymatic assay. The synthesis and structure-activity relationship are also described. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.07.124

文献信息

• [EN] PYRAZOLO` 1,5A! PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS<br/>[FR] COMPOSES DE PYRAZOLO(1,5A)PYRIMIDINE SERVANT D'AGENTS ANTIVIRAUX
  申请人：NEOGENESIS PHARMACEUTICALS INC

  公开号：WO2003101993A1

  公开（公告）日：2003-12-11

  The invention relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

  这项发明涉及抑制丙型肝炎病毒（HCV）复制。具体而言，该发明的实施例提供了抑制HCV RNA依赖性RNA聚合酶酶活性的化合物和方法。该发明还提供了用于预防和治疗HCV感染的组合物和方法。
• Pyrazolopyrimidines as protein kinase inhibitors
  申请人：Paruch Kamil

  公开号：US20060094706A1

  公开（公告）日：2006-05-04

  In its many embodiments, the present invention provides a novel class of pyrazolo[1,5-a]pyrimidine compounds as inhibitors of protein and/or checkpoint kinases, methods of preparing such compounds, pharmaceutical compositions including one or more such compounds, methods of preparing pharmaceutical formulations including one or more such compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more diseases associated with the protein or checkpoint kinases using such compounds or pharmaceutical compositions. The invention also relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

  在其多种实施方式中，本发明提供了一种新型的吡唑并[1,5-a]嘧啶化合物类别，作为蛋白质和/或检查点激酶的抑制剂，制备这种化合物的方法，包括一种或多种这样的化合物的制药组合物，制备一种或多种这样的化合物的制药配方的方法，以及使用这样的化合物或制药组合物治疗、预防、抑制或改善与蛋白质或检查点激酶相关的一种或多种疾病的方法。本发明还涉及抑制丙型肝炎病毒（HCV）复制。具体而言，本发明的实施方式提供了化合物和方法，用于抑制HCV RNA依赖性RNA聚合酶酶活性。本发明还提供了用于预防和治疗HCV感染的组合物和方法。
• Pyrazolo[1,5a]pyrimidine compounds as antiviral agents
  申请人：Neogenesis Pharmaceuticals, Inc.

  公开号：US20040038993A1

  公开（公告）日：2004-02-26

  The invention relates to the inhibition of hepatitis C virus (HCV) replication. In particular, embodiments of the invention provide compounds and methods for inhibiting HCV RNA-dependent RNA polymerase enzymatic activity. The invention also provides compositions and methods for the prophylaxis and treatment of HCV infection.

  本发明涉及抑制丙型肝炎病毒（HCV）复制的方法。具体而言，本发明的实施例提供了抑制HCV RNA依赖性RNA聚合酶酶活性的化合物和方法。本发明还提供了用于预防和治疗HCV感染的组合物和方法。
• PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS ANTIVIRAL AGENTS
  申请人：Neogenesis Pharmaceuticals, Inc.

  公开号：EP1511751B1

  公开（公告）日：2008-03-19
• PYRAZOLO [1,5-A] PYRIMIDINES AS PROTEIN KINASE INHIBITORS
  申请人：Schering Corporation

  公开号：EP1934225A1

  公开（公告）日：2008-06-25